Sydney：12/24 22:26:56

Tokyo：12/24 22:26:56

Hong Kong：12/24 22:26:56

Singapore：12/24 22:26:56

Dubai：12/24 22:26:56

London：12/24 22:26:56

New York：12/24 22:26:56

Live Updates  >  Live Update Details

2025-07-29 23:28:07

Novo Nordisk plunges 22% after lowering its full-year guidance. On Tuesday morning, Eastern Time, Novo Nordisk's (NVO) American Depositary Receipts (ADRs) plummeted approximately 22% after the company lowered its full-year guidance. The downgrade was primarily due to challenges in its weight loss drug business, particularly the GLP-1 drug semaglutide, which fell short of expectations. Novo Nordisk's latest full-year sales forecast is 8%-14%, a significant downward revision from its previous forecast range of 13%-21%. This negative news also affected competitors Eli Lilly (LLY) and Hims & Hers Health (HIMS), with both companies' shares falling approximately 3%.

Real-Time Popular Commodities

Instrument Current Price Change

XAU

 3363.16

73.24

(2.23%)

XAG

 37.003

0.319

(0.87%)

CONC

 67.26

-2.00

(-2.89%)

OILC

 69.48

-2.30

(-3.20%)

USD

 98.678

-1.389

(-1.39%)

EURUSD

 1.1594

0.0001

(0.01%)

GBPUSD

 1.3282

-0.0001

(-0.00%)

USDCNH

 7.1909

-0.0006

(-0.01%)

Hot News

The collapse of US non-farm payroll data and the tariff storm pushed for a September interest rate cut, and Wall Street was wildly bullish on gold.

08-03 08:59

Gold bulls strike back! Non-farm payroll figures trigger a $70 surge, and the battle for $3,400 begins next week.

08-02 19:38

Crude oil prices plummeted after a 6% weekly surge! OPEC+ production increases are sniping bulls, and the oil market faces a "triple trial" next week.

08-02 18:35

The US dollar's defenses collapsed! The non-farm payroll report triggered a 1.06% plunge, with the euro, yen, and Canadian dollar under siege from three directions.

08-02 17:18

Risk Disclosure
Trading stocks, currencies, commodities, futures, bonds, funds or cryptocurrencies involves significant risks. These risks include the loss of part or all of your investment capital, so trading is not suitable for all investors. Before making any financial decision, you should conduct your own due diligence, use your own judgment, and consult a qualified advisor. The content on this website is not specifically directed at you, nor have we considered your financial situation or needs. Information provided on this site may not be real-time or accurate. Prices shown on this website may be provided by market makers rather than exchanges. You are solely responsible for any trades or financial decisions made based on the information from this site, and you must not rely on such information. We make no guarantees regarding any information on the website and assume no responsibility for any trading losses caused by the use of this information. Use, storage, copying, display, modification, dissemination or distribution of the data contained on this site is prohibited without prior written permission. All intellectual property rights in the data provided on this site are reserved by the respective data providers and exchanges.

TURBOFIN TECHNOLOGIES PTY LTD Copyright © 2025 FXBus Ltd